



Glycemic Research Institute
601 Pennsylvania Avenue, N.W.
Suite 900
Washington, D.C. 20004

INSTRUCTIONS for SUBMISSION of DOCUMENTATION

To be licensed to use the GLYCEMIC RESEARCH INSTITUTE CERTIFICATION MARKS and SEALS of APPROVALS, the following forms must be filled out and submitted.

PROTOCOL FOR SUBMITTING DOCUMENTATION

- 1) Clinical trials that meet the guidelines of the FDA and FTC are required.
- 2) Documentation, including Human In Vivo clinical trials, are required.
- 3) Submit the required documentation via FAX: (727) 894-6969
- 4) If Glycemic Solutions conducted the In Vivo clinical trial, include the study number in your paperwork.
- 5) The Medical Advisory Board will review the application and respond via email or phone.
- 6) If the clinical trial data is accepted by the Glycemic Research Institute, directions on obtaining the Seals of Approval will be forthcoming.
- 7) There is no cost for the GRI Seal of Approvals (Pro Bono).



Glycemic Research Institute
601 Pennsylvania Avenue, N.W.
Suite 900
Washington, D.C. 20004

**STANDARD TERMS & CONDITIONS
USE OF THE
GLYCEMIC RESEARCH INSTITUTE SEAL (S) of APPROVAL**

This Agreement is by and between the Glycemic Research Institute (GRI) (herein “GRI”) and the client (herein the “Client”). The Client is defined as *“any company or individual that submits an application to GRI for approval to use the GRI Certification Marks and/or Seals of Approval (herein the “Seals of Approval and/or Seals”)*.

Client applications submitted to GRI for use of the Seals of Approval are only accepted for edible foods, drinks, Nutraceutical, and Pharmaceutical agents (herein the “Product”).

GRI will only accept *documentation* related to the Product in the form of paperwork (sent via e mail, fax or mail), including clinical studies and non-proprietary information related to the product, such as Nutrition Facts label panel and Ingredients panel. No actual product should be submitted with the Application.

Use of any GRI Seals of Approval and/or Certification Marks, and/or licenses provided by the Glycemic Research Institute (GRI) to the Client, are subject to the terms and conditions of this Agreement. Signing of this document by the Client is deemed absolute acceptance and compliance of the terms and conditions stated herein.

FEDERALLY PROTECTED SEALS

The Glycemic Research Institute Seals are Federally protected *Registered Certifications* solely belonging to the Glycemic Research Institute. Any illegal and/or unauthorized use of the Seal (s) will be met by a Federal lawsuit against the perpetrator.

DOCUMENT SUBMISSION

Product documents submitted by the Client to the Glycemic Research Institute for use of the Seals will be presented to the GRI Medical Advisory Board for determination of acceptability.

Upon analysis of the submission documents, the Board will determine if the Product qualifies to use the GRI Seal (s) of Approval. The client will be notified as to the results of the Board. GRI will solely determine if the Product is qualified to utilize the GRI Seals of Approval.

USE OF LOW GLYCEMIC CERTIFICATION MARKS: INTELLECTUAL PROPERTY PROTECTION

The client understands and agrees that products submitted to GRI must pass all GRI Protocols for “Low Glycemic” and/or “Low Glycemic for Diabetics” in order to qualify for the Federal Government Certification Marks and/or Trademarks, as awarded to the Glycemic Research Institute (GRI) (Glycemic.com) (USPTO.gov). Use of these Marks requires applying to GRI and providing clinical documentation that the product submitted has undergone Board Approved, GRI Approved, Human In Vivo Clinical Trials. Following approved Human In Vivo Clinical Trials for any product submitted, and following approval of the said product by GRI, the client agrees not to utilize any “Glycemic” and/or “Low Glycemic” and/or “Low Glycemic for Diabetics” and or similar statement or logo or Seal, other than those Marks belonging to the Glycemic Research Institute. Products that GRI Certifies as “Low Glycemic” shall not bear any Glycemic-Related Seal or Mark or Logo or Certification other than that of the Glycemic Research Institute. Any breach of this protocol can result in legal action. The client understands and agrees that any use of the GRI Marks and/or Seals on a product label or attendant literature prohibits use of any other competing Seal or Mark or Logo or statement in which the term "Low Glycemic" and/or "Low Glycemic for Diabetics" is utilized.

LICENSING LIMITATIONS

The Client may only utilize approved GRI Seals of Approval on labels of the Product submitted, and websites as owned and controlled by the Client. Distributors of the Client may not use any GRI Seal of Approval without submitting a request, and obtaining written approval from GRI.

Any use of the GRI Seals of Approval outside the scope of this Agreement can result in termination of the license. In said cases, the Client agrees to immediately Cease & Desist using any GRI Seal of Approval, including removing said Seals from a website, within 24 hours notice from GRI.

USE OF NAME

The client agrees not to use GRI's name or data in any manner which might cause harm to GRI's reputation and/or business. Under no circumstances is the name of GRI to be published, either alone or in association with that of any other party, without prior written approval from the Glycemic Research Institute.

USE OF THE SEALS OF APPROVAL

The client agrees not to use any Glycemic Research Institute Seal without written authorization from GRI, not to duplicate a similar mark for the purpose of circumventing the legal trademark and certification marks of GRI, not to defame said marks, not to use GRI's copyrighted material without written prior approval from GRI, and not to copy (electronically or otherwise) GRI's Seal literature without prior written approval from GRI. The client agrees to follow the guidelines as set forth by GRI for using the Seals of Approval in the public domain.

CHANGES IN INGREDIENTS

If any changes are made to the original product submitted, a new application must be made and submitted. GRI denies any legal responsibility whatsoever for false FDA labeling claims made by the client.

ILLEGAL MODIFICATION OF GRI CERTIFICATION MARKS

No modifications may be made to the Federally Registered GRI Marks. This includes utilizing the Mark claims of “Low Glycemic” and/or “Low Glycemic for Diabetics” and/or “Bajo Indice Glucemico” as on the Spanish Seal/Mark and/or “Non-Cephalic” as on the Cephalic Seal/Mark and/or “Certified Nanotechnology” as on the Nano Seal/Mark and/or “Low Glycemic Pet Food of the Year” as on the Pet Food Seal/Mark, without the circle Seal/Mark that states “Certified by the Glycemic Research Institute.” Failure to comply with the specific guidelines herein will result in revocation of validation from the Glycemic Research Institute regarding any claims as related to the marks above.

WEBSITE APPROVAL

If the Client is issued a license to use the GRI Seals of Approval, and wishes to display the Seals at their website, GRI must approve all use of the Seals at the Client website. Client websites displaying the GRI Seals of Approval will be monitored by GRI Legal Department on a monthly basis, and any inappropriate use of the Seals will be reported to the Client by GRI for immediate remedial action. If the Client does not take immediate action (within 24 hours) to repair and remove any inappropriate use of the GRI Seals, the Client can be held responsible for legal costs and damages.

PRO BONO

Use of the GRI Seals of Approvals and Certification Marks are totally subject to prior written approval from GRI. There is no cost for use of the Seals/Marks, and use of the Seals/Marks is not automatically granted to any party.

I hereby agree to the terms of this Agreement.

Client Signature

Date

Client Printed Name

Corporate Title

Corporation Name

Corporation Address



Glycemic Research Institute
601 Pennsylvania Avenue, N.W.
Suite 900
Washington, D.C. 20004



Glycemic Research Institute
601 Pennsylvania Avenue, N.W.
Suite 900
Washington, D.C. 20004

SUBMISSION & APPLICATION FORM

Company Name & Address

Date _____

Study # _____

E-Mail _____

Web _____

Contact Person _____

Phone _____

Title _____

Fax _____

Name of Product Submitted _____

Is the Name of This Product Trademarked with the USPTO ? _____

Is this Product Patented with the USPTO ? _____

Description of Product _____

If approved, do you intend to use the GRI Seals on a website, and if so, list the web address _____

Total Number of Products Submitted _____

For each product submitted, fill out an additional form.

Certification Mark Applied For:

<input type="checkbox"/>	Low Glycemic
<input type="checkbox"/>	Low Glycemic for Diabetics
<input type="checkbox"/>	Low Glycemic Latin Certification
<input type="checkbox"/>	Low Cephalic Index
<input type="checkbox"/>	Certified Nanotechnology
<input type="checkbox"/>	Low Glycemic Pharmaceuticals
<input type="checkbox"/>	Other *

* The FDA and FTC require Board Approved Human In Vivo clinical trials for use of any **Low Glycemic** statement and/or **Non-Cephalic** statement as made on a label or attendant literature, and/or for use of the GRI Seals.

** The FDA and FTC require Board Approved Human In Vivo clinical trials using diabetics for use of the “**Low Glycemic for Diabetics**” Seal.

DOCUMENTS REQUIRED WITH THIS APPLICATION

The following documents must be submitted with this form:

- Human In Vivo Clinical Study
- Product Label, including Ingredients Panel
- Signed *Standard Terms and Agreement document*
- Signed *Authority to Approve Use of the Seals of Approval document*



Glycemic Research Institute
601 Pennsylvania Avenue, N.W.
Suite 900
Washington, D.C. 20004

**AUTHORITY TO APPROVE
USE OF THE SEALS of APPROVAL**

The client fully understands that only the Glycemic Research Institute has the authority to grant use of the Seals of Approvals and Certification Marks. Glycemic Solutions does not have the right or authority to approve or grant any use whatsoever of the GRI Seals of Approvals and Certification Marks. The Glycemic Research Institute and Glycemic Solutions are separate corporations.

Prior written authority from the Glycemic Research Institute is required before using any of the GRI Seals of Approval in any format whatsoever, including labels, websites, and marketing literature.

The GRI Seals of Approval may not be copied from any website, and must be obtained from an authorized GRI agent, in electronic form. Any illegal use of the GRI Seals of Approval will be met with a Federal lawsuit. The GRI Seals of Approval are Federally protected property.

Client Signature

Date

Client Printed Name

Corporation

*END GRI SUBMISSION FORMS FOR SEALS OF APPROVAL
LAST UPDATE: April 2008
COPYRIGHT © GRI 2008*